Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Completed · Phase 1

Conditions studied: Cancer

In brief

The purpose of this study is to determine what dose of GSK1120212 can be given safely in combination with at least one other drug that is already approved to treat cancer. This study will test the safety of up to 6 different GSK1120212 study treatment combinations (GSK1120212 plus either docetaxel, erlotinib, pemetrexed, pemetrexed + carboplatin, pemetrexed + cisplatin, or nab-paclitaxel). The doses identified in this study may be used in future trials to test whether the combination treatment is a safe and effective therapy for subjects with metastatic lung and/or pancreatic cancers.

Key facts

Study ID

NCT01192165

Run by

GlaxoSmithKline

People needed

169

Starts

2010-09-14

Expected to finish

2013-10-07

Last updated by the study team

2017-11-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation.
• Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists.
• The subject has a radiographically measurable tumor.
• The subject is able to carry out daily life activities without difficulty.
• The subject is able to swallow and retain oral medication.
• The subject does not have significant side effects from previous anti-cancer treatment.
• The subject has adequate organ and blood cell counts.
• Sexually active subjects must use medically acceptable methods of contraception during the course of the study.

You may not qualify if…

• The subject has had major surgery or received certain types of cancer therapy within 2-3 weeks before starting the study.
• The subject has a brain tumor.
• Current severe, uncontrolled systemic disease.
• History of clinically significant heart, lung, or eye/vision problems.
• The subject has high blood pressure that is not well-controlled with medication.
• The subject has a permanent pacemaker.
• The subject is pregnant or breastfeeding.
• Positive for Hepatitis B, Hepatitis C, or HIV.

Where it is running

• GSK Investigational Site — Scottsdale, Arizona, United States
• GSK Investigational Site — Duarte, California, United States
• GSK Investigational Site — Sacramento, California, United States
• GSK Investigational Site — Denver, Colorado, United States
• GSK Investigational Site — Las Vegas, Nevada, United States
• GSK Investigational Site — Albany, New York, United States
• GSK Investigational Site — Greenville, South Carolina, United States
• GSK Investigational Site — Nashville, Tennessee, United States
• GSK Investigational Site — Dallas, Texas, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — Tyler, Texas, United States
• GSK Investigational Site — Norfolk, Virginia, United States
• GSK Investigational Site — Vancouver, Washington, United States
• GSK Investigational Site — Toronto, Ontario, Canada
• GSK Investigational Site — Caen, France
• GSK Investigational Site — Marseille, France
• GSK Investigational Site — Saint-Herblain, France
• GSK Investigational Site — Toulouse, France
• GSK Investigational Site — Seoul, South Korea
• GSK Investigational Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.